ScholarMate
English简体中文繁體中文
Customer service: 400-1616-289
Sign inSign up
Journal article

Daphnetin contributes to allergen-induced Th2 cytokine expression and type 2-immune responses in atopic dermatitis and asthma

Zhang, Yi; Qu, Lu; Sun, Yun; Lin, YuPing; Zeng, Jing; He, LiXia; Li, Xiucun; Gu, Wen; Nie, Jian; Yu, Xiaoling; Tong, XiaoYun*; Huang, Feng*山东大学; 云南大学; 1
Food & Function2022-11-28DOI: 10.1039/d2fo02518c
3Cited by28Reads
CiteSave
Share

Abstract

Daphne koreana Nakai is a cherished medicinal plant in the Changbai Mountain region of China. It can be incorporated into medicinal meals and used for various skin diseases by infiltrating liquor. Daphnetin (7,8-dihydroxycoumarin, Dap.) is a main constituent of D. koreana Nakai, which has been used to treat inflammatory conditions and immune disorders due to its numerous pharmacological activities, including anti-oxidant, anti-inflammatory, analgesic, etc. Atopic dermatitis (AD) and allergic asthma are typical diseases of type 2-immune responses. In the present study, the therapeutic potential of Dap. against AD and allergic asthma was investigated using animal and cell experiments. AD-like lesions were induced by repeated application of 1-chloro-2,4-dinitrobenzene (DNCB) to the shaved dorsal skin of BALB/c mice. Ovalbumin (OVA) induction was utilized to establish a mouse asthma model. A passive cutaneous anaphylaxis (PCA) mouse ear model and immunoglobulin E (IgE)/bovine serum albumin (BSA)-stimulated RBL-2H3 cells were used for in vitro assays. The skin lesions and serum and tissue homogenates of the mice were analyzed using histological analysis, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA), respectively, in order to investigate the anti-AD effects of Dap. Histological analysis was performed on the allergic asthma model to observe inflammatory cell infiltration in the lung tissues. Total IgE and OVA-specific IgE in the serum were measured by ELISA. The levels of inflammatory cytokines in BALF were detected by ELISA. In addition, ELISA and western blotting were performed for the in vitro analysis of RBL-2H3 cells. The results showed that Dap. inhibited the development of DNCB-induced AD-like lesions in the BALB/c mice by reducing the severity of the lesions, epidermal thickness and mast cell infiltration; this was accompanied by reduced levels of IgE and inflammatory cytokines [interleukin (IL)-4, IL-5, IL-9, IL-13, IL-33 and thymic stromal lymphopoietin (TSLP)]. In the allergic asthma model, Dap. reduced the number of infiltrated inflammatory cells in the lung tissues. Moreover, the levels of total serum IgE and OVA-specific IgE were reduced in the high daphnetin dose groups (Dap., -100 mg kg(-1)). Dap. administered at a dose of -100 mg kg(-1) decreased the levels of inflammatory cytokines (IL-4, IL-5, IL-9, IL-13, IL-33 and TSLP in BALF). Furthermore, Dap. administered to IgE-sensitized mice effectively attenuated the IgE-triggered PCA reaction. In vitro, Dap. decreased the expression levels of histamine, IL-4, IL-6, IL-13, MIP-1 alpha and INF-alpha, and reduced the protein expression levels of phosphorylated MAPKs, P-Lyn and P-syk in the RBL-2H3 cells. Therefore, Dap. can be represented as a potential therapeutic strategy for the treatment of allergic inflammatory conditions via immunoregulation.

Disciplines and keywords

Keywords
PASSIVE CUTANEOUS ANAPHYLAXISMAST-CELLSANTIALLERGIC ACTIVITYIN-VITROACTIVATIONINHIBITIONIL-1IGEINFLAMMATIONDERIVATIVES
Related
Loading…

Could not load papers. Please retry.

Retry

Publication info

Publication status
Published
Journal
Food & Function
Publication date
2022-11-28
Volume / issue
Vol. 13, Issue 23
Pages
12383-12399
DOI
10.1039/d2fo02518c
Language
ENGLISH
Output indexing
SCIE
Funding acknowledgment
211 Project and Key Laboratory of Innovative Research Projects of College of Pharmacy of Jinan University; National Research Foundation of National Natural Science Foundation of China [81960784, 81760741, 81760775, 81860760, 82060751]; Yunnan Provincial Science and Technology Department - Applied Basic Research Joint Special Funds of Chinese Medicine [202001AZ070001-039]; Key Project of Yunnan Provincial Science and Technology Department [2019FA035, 202001AU070102]; Yunnan Innovation Team of Application Research on TCM Theory of Prevention Disease at Yunnan University of TCM [2017HC011]; Department of Science and Technology of Yunnan Province [202001AU070102, 2018FF001(-050), 2019FF002(-010)]

Authors

  • Z

    Zhang, Yi (First author)

    yunnan univ tradit chinese med

  • Q

    Qu, Lu

    yunnan univ tradit chinese med

View all 12 authorsShow fewer authors
  • S

    Sun, Yun

    yunnan univ tradit chinese med

  • L

    Lin, YuPing

    yunnan univ tradit chinese med

  • Z

    Zeng, Jing

  • H

    He, LiXia

    2 · wannan med coll

  • L

    Li, Xiucun

    shandong univ

  • G

    Gu, Wen

    yunnan univ tradit chinese med

  • N

    Nie, Jian

    yunnan univ tradit chinese med

  • Y

    Yu, Xiaoling

    yunnan univ

  • T

    Tong, XiaoYun (Corresponding)

    1 · yunnan univ

  • H

    Huang, Feng (Corresponding)

    yunnan univ tradit chinese med · yunnan univ

Sign in for more features

  • Save this paper in My collections
  • Claim your outputs and generate promotion materials
  • Follow authors for new outputs
  • Join groups and collaborate
Sign up / Sign in

Products

  • ScholarMate
  • InnoCity
  • IRISaaS

Support

  • Help Center
  • Privacy Policy
  • Terms of Service

Contact

Online support: []
Customer service: 400-1616-289
Email: support@scholarmate.com

Follow or download ScholarMate

WeChat QR code
WeChat official account
App download QR code
Download the app
OutputsResearchersResearch institutionsResearch newsIRISaaS

©2026 深圳市科研之友网络服务有限公司

Public security registration badge粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417